These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 28757264)

  • 1. Baseline Parameters in Clinical Trials for Nonalcoholic Steatohepatitis: Recommendations From the Liver Forum.
    Patel YA; Imperial JC; Muir AJ; Anstee QM; DeBrota D; Dimick-Santos L; Filozof C; Mehta R; Sanyal AJ; Schabel E; Neuschwander-Tetri BA; Miller V;
    Gastroenterology; 2017 Sep; 153(3):621-625.e7. PubMed ID: 28757264
    [No Abstract]   [Full Text] [Related]  

  • 2. Attribution of Nonalcoholic Steatohepatitis as an Etiology of Cirrhosis for Clinical Trials Eligibility: Recommendations From the Multi-stakeholder Liver Forum.
    Noureddin M; Chan JL; Barradas K; Dimick-Santos L; Schabel E; Omokaro SO; Anania FA; Myers RP; Miller V; Sanyal AJ; Chalasani N;
    Gastroenterology; 2020 Aug; 159(2):422-427.e1. PubMed ID: 32353369
    [No Abstract]   [Full Text] [Related]  

  • 3. Recommendations for Diagnosis, Referral for Liver Biopsy, and Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis.
    Spengler EK; Loomba R
    Mayo Clin Proc; 2015 Sep; 90(9):1233-46. PubMed ID: 26219858
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): prevalence, therapeutic innovations, and stumbling blocks for clinical development.
    Alkhouri N
    Expert Opin Investig Drugs; 2020 Feb; 29(2):115-116. PubMed ID: 31971024
    [No Abstract]   [Full Text] [Related]  

  • 5. Foreword. Nonalcoholic Fatty Liver Disease.
    Day CP; Anstee QM
    Semin Liver Dis; 2015 Aug; 35(3):203-6. PubMed ID: 26378638
    [No Abstract]   [Full Text] [Related]  

  • 6. Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease: An update.
    Athyros VG; Tziomalos K; Katsiki N; Doumas M; Karagiannis A; Mikhailidis DP
    World J Gastroenterol; 2015 Jun; 21(22):6820-34. PubMed ID: 26078558
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of lifestyle interventions in NAFLD (nonalcoholic fatty liver disease) - how are clinical trials affected?
    Michel M; Schattenberg JM
    Expert Opin Investig Drugs; 2020 Feb; 29(2):93-97. PubMed ID: 31933385
    [No Abstract]   [Full Text] [Related]  

  • 8. A non-invasive prediction model for non-alcoholic steatohepatitis in paediatric patients with non-alcoholic fatty liver disease.
    Eng K; Lopez R; Liccardo D; Nobili V; Alkhouri N
    Dig Liver Dis; 2014 Nov; 46(11):1008-13. PubMed ID: 25106814
    [TBL] [Abstract][Full Text] [Related]  

  • 9. How to Approach a Patient With Nonalcoholic Fatty Liver Disease.
    Tilg H
    Gastroenterology; 2017 Aug; 153(2):345-349. PubMed ID: 28647352
    [No Abstract]   [Full Text] [Related]  

  • 10. Guidelines of prevention and treatment of nonalcoholic fatty liver disease (2018, China).
    Fan JG; Wei L; Zhuang H;
    J Dig Dis; 2019 Apr; 20(4):163-173. PubMed ID: 30444584
    [No Abstract]   [Full Text] [Related]  

  • 11. Editorial: Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis: An Epidemic that will Boost the Incidence of Cardiovascular Morbidity and Mortality.
    Athyros VG; Doumas M
    Curr Vasc Pharmacol; 2018; 16(3):206-208. PubMed ID: 29598814
    [No Abstract]   [Full Text] [Related]  

  • 12. Consensus: guidelines: best practices for detection, assessment and management of suspected acute drug-induced liver injury during clinical trials in patients with nonalcoholic steatohepatitis.
    Regev A; Palmer M; Avigan MI; Dimick-Santos L; Treem WR; Marcinak JF; Seekins D; Krishna G; Anania FA; Freston JW; Lewis JH; Sanyal AJ; Chalasani N
    Aliment Pharmacol Ther; 2019 Mar; 49(6):702-713. PubMed ID: 30761572
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Metabolic Syndrome and Its Influence on Nonalcoholic Steatohepatitis.
    Kanwar P; Kowdley KV
    Clin Liver Dis; 2016 May; 20(2):225-43. PubMed ID: 27063266
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nonalcoholic Fatty Liver Disease.
    Sweet PH; Khoo T; Nguyen S
    Prim Care; 2017 Dec; 44(4):599-607. PubMed ID: 29132522
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Genetics of Nonalcoholic Fatty Liver Disease: Spotlight on PNPLA3 and TM6SF2.
    Anstee QM; Day CP
    Semin Liver Dis; 2015 Aug; 35(3):270-90. PubMed ID: 26378644
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Defining Improvement in Nonalcoholic Steatohepatitis for Treatment Trial Endpoints: Recommendations From the Liver Forum.
    Cheung A; Neuschwander-Tetri BA; Kleiner DE; Schabel E; Rinella M; Harrison S; Ratziu V; Sanyal AJ; Loomba R; Jeannin Megnien S; Torstenson R; Miller V;
    Hepatology; 2019 Nov; 70(5):1841-1855. PubMed ID: 31034092
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epidemiology and Natural History of Nonalcoholic Fatty Liver Disease.
    Satapathy SK; Sanyal AJ
    Semin Liver Dis; 2015 Aug; 35(3):221-35. PubMed ID: 26378640
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Editorial: Recent News on Statins for the Treatment of Non-Alcoholic Fatty Liver Disease/Non-Alcoholic Steatohepatitis.
    Athyros VG; Katsiki N; Doumas M
    Curr Vasc Pharmacol; 2018 Jan; 16(2):104-106. PubMed ID: 29210655
    [No Abstract]   [Full Text] [Related]  

  • 19. Nonalcoholic fatty future disease.
    Polyzos SA; Mantzoros CS
    Metabolism; 2016 Aug; 65(8):1007-16. PubMed ID: 26805015
    [No Abstract]   [Full Text] [Related]  

  • 20. Nonalcoholic Fatty Liver Disease and Incident Cardiac Events: The Multi-Ethnic Study of Atherosclerosis.
    Zeb I; Li D; Budoff MJ; Katz R; Lloyd-Jones D; Agatston A; Blumenthal RS; Blaha MJ; Blankstein R; Carr J; Nasir K
    J Am Coll Cardiol; 2016 Apr; 67(16):1965-6. PubMed ID: 27102512
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.